From Scalpel to Light · Episode 9 of 10 · 23 min
Light Enters the Clinic
On the day optogenetics won the Nobel Prize, no optogenetic therapy was approved anywhere. The episode audits the clinic: a blind man who partly regained sight in 2021 with an algal protein and goggles, Nanoscope's MOGENRY under FDA review, an optical cochlear implant not yet in any human, and light-paced hearts in animals. It weighs routes around gene modification and four barriers, including opaque tissue and ethics.
Who's who
- Edward Boyden+1 more episodeMIT scientist whose lab created the red-shifted channels used clinically
- José-Alain SahelCo-led the 2021 report of partial vision recovery in a blind patient
- Botond RoskaCo-led the 2021 vision-recovery report
- Zhuo-Hua PanWayne State vision scientist whose retina work underpinned RetroSense
- Tobias MoserGöttingen scientist leading the optical cochlear implant effort
- Dirk TraunerChemist and founder of photopharmacology
- Bryan RothPharmacologist who helped build designer receptors in 2007
- Karl Deisseroth+3 more episodes2026 Nobel laureate for optogenetics
Where it happens
- Dallas, Texas+2 more episodesSite of the first RetroSense patient dosing and Nanoscope's base
- Paris, France+5 more episodesGenSight's base and site of the 2021 vision-recovery work
- Göttingen, GermanyHome of the optical cochlear implant effort
- Samarkand, UzbekistanUNESCO adopted its neurotechnology ethics recommendation there in 2025
Timeline
- March 2016First patient dosed in the RetroSense optogenetic trial in Dallas
- May 24, 2021Partial recovery of visual function in a blind man reported
- October 25, 2021Chile amends its constitution to protect brain activity
- November 12, 2025UNESCO adopts its Recommendation on the Ethics of Neurotechnology
- September 9, 2026FDA accepts Nanoscope's MOGENRY application
- October 5, 2026Nobel Prize awarded; no optogenetic therapy approved anywhere
Still debated
Whether Nanoscope's daylight-tuned protein outperforms the goggles-plus-channel approach is not settled by head-to-head data, and the vision gains in daily life are not yet established. The first RetroSense trial produced no public account of useful vision, and the optical cochlear implant timeline is uncertain.